{"id":"W4379468067","doi":"10.1038/s41591-023-02399-0","title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Duke Cancer Institute; Chugai Pharmaceutical; Genentech; Menarini Group; PharmaMar; Astellas Pharma; Eisai; Springworks Therapeutics; Seagen; Mereo BioPharma; MacroGenics; Silverback Therapeutics; Actuate Therapeutics; Loxo Oncology; Astex Pharmaceuticals; Invitae; AstraZeneca; Novocure; Jazz Pharmaceuticals; Merck KGaA; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; Spectrum Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Samsung; Bristol-Myers Squibb; Amgen; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; GlaxoSmithKline","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Cancer; Ataxia-telangiectasia; Cancer research; Oncology; Clinical trial; Internal medicine; DNA damage; Pharmacology; Biology; DNA; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001957273,0.001199407,0.001450845,0.0003533101,0.0003201249,0.0008532241,0.0005754193,0.001105037,0.003273538],"category_scores_gemma":[0.0009136086,0.0002708616,0.0008238189,0.000300433,0.0005722795,0.0006905612,0.0002571412,0.002256559,0.0006116962],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008995651,"about_ca_system_score_gemma":0.000945761,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008538276,"about_ca_topic_score_gemma":0.002248743,"domain_scores_codex":[0.9995375,0.0002104649,0.00002176943,0.00007357162,0.00007801356,0.00007865385],"domain_scores_gemma":[0.9994712,0.0001071198,0.00009687205,0.00004297876,0.00006183414,0.0002200163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4370713,0.04888565,0.01173406,0.001692482,0.001681069,0.0006874342,0.0004043649,0.008212419,0.2763285,0.0009172833,0.02139056,0.1909949],"study_design_scores_gemma":[0.2950478,0.6117215,0.03028765,0.0001227432,0.0009150535,0.0007735047,0.000100784,0.006263578,0.04382111,0.0008700546,0.01001845,0.00005782731],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852358,0.002602731,0.001214893,0.0008224219,0.0001295982,0.002463047,0.003157527,0.0002026974,0.004171317],"genre_scores_gemma":[0.9777435,0.002024774,0.002943337,0.0009905002,0.0001556871,0.00274864,0.00786711,0.00007153022,0.00545486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003273538,"threshold_uncertainty_score":0.0109511,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01098829602532976,"score_gpt":0.3373821352244508,"score_spread":0.3263938391991211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}